<DOC>
	<DOCNO>NCT00721747</DOCNO>
	<brief_summary>The purpose study determine many pathological complete response achieve patient treat taxotere® ( T ) follow Myocet® ( M ) Cyclophosphamide ( MC ) first line treatment HER2 negative brest cancer patient .</brief_summary>
	<brief_title>Taxotere® , Followed Myocet® Cyclophosphamide First Line Treatment HER2 Neg Breast Cancer</brief_title>
	<detailed_description>Phase II , open , randomized clinical trial , evaluate sequential Taxotere® , follow Myocet® Cyclophosphamide first line treatment her2 negative breast cancer patient . The purpose study determine many pathological complete response achieve patient treat taxotere® ( T ) follow Myocet® ( M ) Cyclophosphamide ( MC ) first line treatment HER2 negative brest cancer patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Brest adenocarcinoma stage II/III Female Informed consent sign HER2 negative Age &gt; 18 year old ECOG &lt; 1 Proper organic function regard follow criterion : 1 . ANC &gt; 2,0 x 109L , platelet &gt; 100 x 109L hemoglobin &gt; 10g/dL ( transfusion allow ) 2 . Hepatic Function : i.Bilirubin &lt; 1,5 x UNL ii.AST , ALT &lt; 2,5 x UNL iii.Alkaline phosphatase &lt; 5 UNL iv.Patients AST /or ALT &gt; 1.5 x UNL alkaline phosphatase &gt; 2.5 x UNL select study c.Renal function : creatinine &lt; 1,25 x UNL , creatinine clearance &gt; 60 mL/min d.Normal Cardiac function , confirm FEVI &gt; 50 % electrocardiogram . Patients available treatment follow must treat investigator coinvestigator site Negative pregnancy test ( perform 7 day treatment ) Previous treatment breast cancer ( CT , RT , IT , HT ) Stages IIIb , IIIc IV invasive bilateral breast cancer Previous neoplasias treat Anthracyclines Taxanes ( Paclitaxel Docetaxel ) Pregnant breastfeed female Neurotoxicity Grade 2 FEV≤50 % cardiac disease anthracyclines contraindicate Other severe disease regard investigator criterion Any neurological psychiatric pathology Previous neoplasia different breast cancer except : 1. skin cancer ( melanoma ) 2 . In situ cervix Carcinoma 3 . Ipsilateral situ ductal carcinoma 4 . In situ lobular situ carcinoma 5 . Any carcinoma without evidence disease last 10 year Treatment chronic corticoid ( except patient start 6 month inclusion low dosage ( * 20 mg methylprednisolone equivalent ) Concomitant treatment Hormone ovarian replacement therapy Contraindication corticoid Concomitant treatment another investigational drug Included another clinical trial drug 30 day inclusion study Concomitant treatment another anticancer therapy Male patient Hypersensibility study drug component</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>breast cancer patient her2 negative pathological response</keyword>
</DOC>